Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response.
This study attempts to characterize thallium-201 (201TI) uptake in patients with bone and soft-tissue sarcoma and to compare these findings with gallium-67 (67Ga) and bone scintigraphy with emphasis on evaluating tumor viability before and after chemotherapy. Thirty-eight patients with surgically-proven sarcomas were evaluated. All patients had gallium and thallium studies. Nineteen patients underwent pre- and post-chemotherapy thallium and evaluation. Seven patients also had technetium-99m-MDP (99mTc-MDP) bone scintigraphy comparisons. Pathologic changes pre- and postchemotherapy were graded on the basis of %tumor necrosis as defined histologically. Scintigraphic comparisons demonstrated a high degree of correlation with 201TI and poor correlation with 99mTc-MDP. Thallium-201 was superior to 99mTc-MDP and 67Ga in predicting tumor response to chemotherapy as determined by %tumor necrosis determined histologically. Gallium was superior to Tc-MDP in predicting response to chemotherapy. However, both 67Ga and 99mTc-MDP appear to be affected by factors other than tumor activity.
Ramanna
L
L
Department of Nuclear Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048.
Waxman
A
A
Binney
G
G
Waxman
S
S
Mirra
J
J
Rosen
G
G
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002951:Citrates; D019343:Citric Acid; D005260:Female; D005710:Gallium Radioisotopes; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D012509:Sarcoma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D013669:Technetium Tc 99m Medronate; D013794:Thallium Radioisotopes
D000970:Antineoplastic Agents; D002951:Citrates; D005710:Gallium Radioisotopes; D013794:Thallium Radioisotopes; D019343:Citric Acid; D013669:Technetium Tc 99m Medronate